Literature DB >> 20352018

5-HT(1A) Receptor Null Mutant Mice Responding Under a Differential-Reinforcement-of-Low-Rate 72-Second Schedule of Reinforcement.

Jonah J Scott-McKean1, Galen R Wenger, Laurence H Tecott, Alberto C S Costa.   

Abstract

Over the last two decades, our ever-increasing ability to manipulate the mouse genome has resulted in a variety of genetically defined mouse models of depression and other psychiatric and neurological disorders. However, it is still the case that some relevant rodent models for depression and antidepressant action have been validated experimentally in rats only and not in mice. An important example of such models is the operant model of antidepressant action known as differential-reinforcement-of-low-rates 72-second (DRL 72-s). A specific set of drug-induced changes on the performance of rats responding under a DRL 72-s schedule of reinforcement has been shown to be a highly reliable predictor of antidepressant activity in human depressive disorders. The aim of this study is to validate the use of the DRL 72-s schedule in mice by both genetic and pharmacological means. We have analyzed the actions of the specific serotonin reuptake inhibitor (SSRI) fluoxetine and the tricyclic agent desipramine (DMI) on wild-type and 5-hydroxytryptamine 1A receptor-null mutant (5-HT(1A)R KO) mice. In agreement with the literature on rats, we found that fluoxetine produced an acute antidepressant-like effect in 5-HT(1A)R KO mice but not in wild-type (Wt) mice. Additionally, an antidepressant-like effect was observed when DMI was administered to both 5-HT(1A)R KO and Wt mice. In conclusion: through the use of both genetic and pharmacological strategies, this study validates the extension of a protocol involving the DRL 72-s operant schedule of reinforcement as a behavioral model for the action of antidepressants in mice.

Entities:  

Year:  2008        PMID: 20352018      PMCID: PMC2845473          DOI: 10.2174/1876523800801010024

Source DB:  PubMed          Journal:  Open Neuropsychopharmacol J


  30 in total

Review 1.  Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule.

Authors:  James M O'Donnell; Gerard J Marek; Lewis S Seiden
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

2.  Acute uptake inhibition increases extracellular serotonin in the rat forebrain.

Authors:  J J Rutter; S B Auerbach
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

3.  Increased anxiety of mice lacking the serotonin1A receptor.

Authors:  C L Parks; P S Robinson; E Sibille; T Shenk; M Toth
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

4.  The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial.

Authors:  R M Berman; A Anand; A Cappiello; H L Miller; X S Hu; D A Oren; D S Charney
Journal:  Biol Psychiatry       Date:  1999-05-01       Impact factor: 13.382

5.  Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat.

Authors:  I Hervás; C M Queiroz; A Adell; F Artigas
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

6.  Rats selectively bred for responsiveness to 5-hydroxytryptamine(1A) receptor stimulation: differences in differential reinforcement of low rate 72-second performance and response to serotonergic drugs.

Authors:  M S Cousins; G Vosmer; D H Overstreet; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

7.  The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.

Authors:  L Johansson; D Sohn; S O Thorberg; D M Jackson; D Kelder; L G Larsson; L Rényi; S B Ross; C Wallsten; H Eriksson; P S Hu; E Jerning; N Mohell; A Westlind-Danielsson
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

8.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

9.  Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine.

Authors:  J J Rutter; C Gundlah; S B Auerbach
Journal:  Neurosci Lett       Date:  1994-04-25       Impact factor: 3.046

10.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

View more
  1 in total

1.  Substitution of 5-HT1A receptor signaling by a light-activated G protein-coupled receptor.

Authors:  Eugene Oh; Takashi Maejima; Chen Liu; Evan Deneris; Stefan Herlitze
Journal:  J Biol Chem       Date:  2010-07-19       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.